First National Trust Co bought a new position in Kenvue Inc. (NYSE:KVUE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 57,127 shares of the company's stock, valued at approximately $1,220,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Grove Bank & Trust increased its stake in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock valued at $25,000 after buying an additional 947 shares during the period. Geneos Wealth Management Inc. bought a new stake in shares of Kenvue during the 4th quarter valued at about $29,000. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC boosted its position in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Kenvue Stock Up 0.6 %
Shares of Kenvue stock traded up $0.15 on Wednesday, hitting $23.49. The company had a trading volume of 9,646,894 shares, compared to its average volume of 16,084,529. The stock has a market capitalization of $44.89 billion, a price-to-earnings ratio of 44.31, a P/E/G ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock has a 50 day moving average of $21.94 and a 200-day moving average of $22.41. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.
Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.49%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.
Analysts Set New Price Targets
Several brokerages recently commented on KVUE. Canaccord Genuity Group upped their target price on Kenvue from $24.00 to $29.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and cut their target price for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. Piper Sandler upped their target price on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a research report on Monday, February 24th. Finally, Citigroup cut their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $23.75.
Read Our Latest Report on KVUE
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
